# Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

> **NCT01503632** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 570 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BEHAVIORAL:** Behavioral Intervention
- **BEHAVIORAL:** Compliance Monitoring
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mercaptopurine
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Standard Follow-Up Care

## Key facts

- **NCT ID:** NCT01503632
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-21
- **Primary completion:** 2019-06-30
- **Final completion:** 2026-03-31
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01503632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01503632, "Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01503632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*